YU47200A - Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije - Google Patents
Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezijeInfo
- Publication number
- YU47200A YU47200A YU47200A YU47200A YU47200A YU 47200 A YU47200 A YU 47200A YU 47200 A YU47200 A YU 47200A YU 47200 A YU47200 A YU 47200A YU 47200 A YU47200 A YU 47200A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- inhibitors
- bone resorption
- cell adhesion
- sulfonamide derivatives
- formula
- Prior art date
Links
- 208000006386 Bone Resorption Diseases 0.000 title abstract 3
- 230000024279 bone resorption Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000021164 cell adhesion Effects 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100022337 Integrin alpha-V Human genes 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1248998A | 1998-01-23 | 1998-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU47200A true YU47200A (sh) | 2002-11-15 |
Family
ID=21755208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU47200A YU47200A (sh) | 1998-01-23 | 1999-01-16 | Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1049677A1 (enExample) |
| JP (1) | JP2002501054A (enExample) |
| KR (1) | KR20010034319A (enExample) |
| CN (1) | CN1177832C (enExample) |
| AP (1) | AP1269A (enExample) |
| AR (1) | AR014456A1 (enExample) |
| AU (1) | AU752882B2 (enExample) |
| BG (1) | BG104630A (enExample) |
| BR (1) | BR9907735A (enExample) |
| CA (1) | CA2318221A1 (enExample) |
| EA (1) | EA003102B1 (enExample) |
| HR (1) | HRP20000493A2 (enExample) |
| HU (1) | HUP0100520A3 (enExample) |
| ID (1) | ID26219A (enExample) |
| IL (1) | IL137423A0 (enExample) |
| NO (1) | NO318795B1 (enExample) |
| NZ (1) | NZ505613A (enExample) |
| PL (1) | PL341871A1 (enExample) |
| SK (1) | SK10632000A3 (enExample) |
| TR (1) | TR200002160T2 (enExample) |
| TW (1) | TWI247742B (enExample) |
| UA (1) | UA63990C2 (enExample) |
| WO (1) | WO1999037621A1 (enExample) |
| YU (1) | YU47200A (enExample) |
| ZA (1) | ZA99476B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2338275A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1070707A1 (en) * | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| EP1108721A1 (en) * | 1999-12-15 | 2001-06-20 | Aventis Pharma Deutschland GmbH | Thienylalanine derivatives as inhibitors of cell adhesion |
| WO2001047874A1 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| WO2005090329A1 (en) * | 2004-03-24 | 2005-09-29 | Jerini Ag | New compounds for the inhibition of angiogenesis and use of thereof |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| CA2950390C (en) | 2014-05-30 | 2020-09-22 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| CA2970578C (en) | 2014-12-17 | 2024-01-02 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE227567T1 (de) * | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
-
1999
- 1999-01-16 SK SK1063-2000A patent/SK10632000A3/sk unknown
- 1999-01-16 IL IL13742399A patent/IL137423A0/xx unknown
- 1999-01-16 AU AU25181/99A patent/AU752882B2/en not_active Ceased
- 1999-01-16 HR HR20000493A patent/HRP20000493A2/hr not_active Application Discontinuation
- 1999-01-16 PL PL99341871A patent/PL341871A1/xx unknown
- 1999-01-16 CN CNB998040894A patent/CN1177832C/zh not_active Expired - Fee Related
- 1999-01-16 JP JP2000528545A patent/JP2002501054A/ja not_active Abandoned
- 1999-01-16 UA UA2000084983A patent/UA63990C2/uk unknown
- 1999-01-16 AP APAP/P/2000/001863A patent/AP1269A/en active
- 1999-01-16 NZ NZ505613A patent/NZ505613A/xx unknown
- 1999-01-16 ID IDW20001407A patent/ID26219A/id unknown
- 1999-01-16 YU YU47200A patent/YU47200A/sh unknown
- 1999-01-16 EA EA200000785A patent/EA003102B1/ru not_active IP Right Cessation
- 1999-01-16 BR BR9907735-3A patent/BR9907735A/pt not_active IP Right Cessation
- 1999-01-16 CA CA002318221A patent/CA2318221A1/en not_active Abandoned
- 1999-01-16 HU HU0100520A patent/HUP0100520A3/hu unknown
- 1999-01-16 TR TR2000/02160T patent/TR200002160T2/xx unknown
- 1999-01-16 WO PCT/EP1999/000242 patent/WO1999037621A1/en not_active Ceased
- 1999-01-16 EP EP99904789A patent/EP1049677A1/en not_active Withdrawn
- 1999-01-16 KR KR1020007008041A patent/KR20010034319A/ko not_active Abandoned
- 1999-01-22 ZA ZA9900476A patent/ZA99476B/xx unknown
- 1999-01-29 AR ARP990100244A patent/AR014456A1/es not_active Application Discontinuation
- 1999-04-30 TW TW088100862A patent/TWI247742B/zh active
-
2000
- 2000-07-21 NO NO20003765A patent/NO318795B1/no unknown
- 2000-07-21 BG BG104630A patent/BG104630A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1177832C (zh) | 2004-12-01 |
| KR20010034319A (ko) | 2001-04-25 |
| AP1269A (en) | 2004-04-03 |
| CN1293662A (zh) | 2001-05-02 |
| BG104630A (en) | 2001-04-30 |
| CA2318221A1 (en) | 1999-07-29 |
| TWI247742B (en) | 2006-01-21 |
| HUP0100520A3 (en) | 2002-11-28 |
| UA63990C2 (uk) | 2004-02-16 |
| NZ505613A (en) | 2002-11-26 |
| ID26219A (id) | 2000-12-07 |
| HUP0100520A1 (hu) | 2001-07-30 |
| EP1049677A1 (en) | 2000-11-08 |
| EA200000785A1 (ru) | 2001-02-26 |
| EA003102B1 (ru) | 2002-12-26 |
| AP2000001863A0 (en) | 2000-09-30 |
| AR014456A1 (es) | 2001-02-28 |
| WO1999037621A1 (en) | 1999-07-29 |
| AU752882B2 (en) | 2002-10-03 |
| TR200002160T2 (tr) | 2001-07-23 |
| BR9907735A (pt) | 2000-10-17 |
| SK10632000A3 (sk) | 2001-02-12 |
| NO20003765L (no) | 2000-09-25 |
| AU2518199A (en) | 1999-08-09 |
| IL137423A0 (en) | 2001-07-24 |
| PL341871A1 (en) | 2001-05-07 |
| NO318795B1 (no) | 2005-05-09 |
| ZA99476B (en) | 1999-08-05 |
| JP2002501054A (ja) | 2002-01-15 |
| HRP20000493A2 (en) | 2001-06-30 |
| NO20003765D0 (no) | 2000-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001842A0 (en) | Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists. | |
| YU47200A (sh) | Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije | |
| CA2225366A1 (en) | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them | |
| MX9709521A (es) | Compuestos heterociclicos. | |
| CA2371789A1 (en) | Novel guanidine derivatives as inhibitors of cell adhesion | |
| MY120842A (en) | 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use. | |
| MY114944A (en) | Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use | |
| PL350891A1 (en) | Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase | |
| YU92201A (sh) | Derivati naftiridina, postupci za njihovo dobijanje, njihova upotreba i farmaceutske kompozicije koje ih uključuju | |
| YU89701A (sh) | Substituisani derivati purina kao inhibitori adhezije ćelije | |
| EP1019047A4 (en) | ANTITHROMBOTIC AGENTS | |
| EP1027051A4 (en) | ANTITHROMBOTIC AGENTS | |
| AU2001278503A1 (en) | Novel guanidino derivatives as inhibitors of cell adhesion | |
| AU1434201A (en) | Antithrombotic agents | |
| EP0980366A4 (en) | ANTITHROMOSIS |